Medicinal Products
Dail Éireann — 2026-06-17
============================================================

Jennifer Carroll MacNeill (FG), Dún Laoghaire

It was Úna Ennis who coined the phrase "time is muscle". I am grateful to her for her engagement and advocacy all the way through. The first thing is that we are trying to get the drug physically into the country. My officials have been working on that for some time in anticipation of what we hoped would be a positive response. Of course, it is not just a decision whether to give the drug or not. It is also a decision about whether the drug is effective and for whom it is effective. It is a complicated balance and we must always defer to the scientists on these decisions as well, recognising that Ireland remains a country that believes in science.
We are trying to get the drug physically into the country. This is a high-tech drug and not one that is put on the back of a van and sent to a pharmacy. Due to the way in which it is given, we are trying to work out whether this is something we can do more quickly in acute settings and how we can most quickly get this drug to the boys who need it so badly. Our broad approach is one of trying to give maximum access to it but I will defer to clinicians on who the appropriate people are to get it.
Yesterday, I was meeting with the European health ministers. We had a working lunch specifically on medicines and the challenge of most favoured nation, MFN, access to medicines. We have been trying to work in different ways on two things. As a small country Ireland, like the Benelux countries, Croatia and other small countries, has a difficulty with access to drugs. If we look at drug companies making applications, they are making it to the likes of France, Germany and other huge markets. We are just not in the same space. We do not have the same visibility. We are trying to partner with other countries to create a bigger market so we can be more attractive and also so we can negotiate on more attractive terms.
I feel that the only group with all of the information are the drug companies and that the member states are working somewhat against each other in terms of each of them making individual negotiations because of the way the European treaty is structured and health being a national competence. It is something we need to reflect on. I am working with other European health ministers to find a way to streamline the way the HTA process works, reduce some of the national country administrative burden, make Europe a more powerful block, and rebalance that balance of power, crucially so that patients get access and so the Irish State can spend as much money as possible in getting as many drugs as possible for the broadest range of people. That will not always result in positive decisions by the HSE. I need to say that loudly. We have had difficult days on that, too, but we are desperately trying to take the right approach in every way.

---

Source: Houses of the Oireachtas. Licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). The Official Report is revised after first publication; the fetch timestamp below identifies the version quoted.

Record URI: https://data.oireachtas.ie/akn/ie/debateRecord/dail/2026-06-17/debate/main
Retrieved: 2026-09-21T01:01:09+00:00
Sitting date: 2026-06-17